Biotech Firm Abpro Faces Nasdaq Delisting Over Capital Standards

Abpro shares suspended as Nasdaq enforces equity rules. The biotech appeals the delisting decision while advancing its cancer drug trials and warns of OTC market risks.

Shares and warrants of Abpro Corporation were suspended from trading on the Nasdaq at the start of today's session. The biopharmaceutical company failed to meet the exchange's minimum equity requirements by the stipulated deadline. This development casts a shadow over the firm's future listing status, threatening a permanent move to the unregulated over-the-counter market, despite reported progress in its clinical pipeline.

Operational Efforts Amid Listing Crisis

The potential delisting comes at a time when Abpro has been actively working to streamline its operations. Notably, the company executed a reverse stock split in November 2025 in an attempt to regain compliance with exchange rules. Management has concurrently reduced operating expenses by approximately 60 percent year-over-year.

On the clinical front, Abpro recently achieved a significant milestone. In January, alongside partner Celltrion, it received U.S. Investigational New Drug (IND) approval for a Phase 1 study of its antibody candidate, ABP-102, targeting solid tumors. Patient enrollment for these clinical trials is scheduled to commence in the first half of 2026. To fund these and other operational goals, Abpro has access to equity financing of up to $44 million, which it states should secure its operations through the end of 2026.

Formal Appeal Process Underway

The Nasdaq Listing Qualifications panel formally notified Abpro of the delisting decision this past Saturday. The action was triggered by non-compliance with Listing Rule 5550(b)(1), as the company could not demonstrate adherence to the mandated equity standards by the February 16 deadline. In response, Abpro's management has announced it will appeal the ruling.

The company has a 15-day window from receipt of the notice to request a review by the Nasdaq Listing and Hearing Review Council. The outcome of this appeal remains uncertain. In light of this ambiguity, Abpro is already preparing for the possibility of trading on alternative platforms.

Investor Risks in the OTC Marketplace

Should the appeal be unsuccessful, Abpro expects its securities to be quoted on the OTC Pink Market under the familiar symbols "ABP" and "ABPWW." The company explicitly cautions investors that such a transition carries substantial drawbacks, including significantly less information availability and reduced transparency compared to a national exchange.

Trading in the over-the-counter arena is also typically characterized by markedly lower liquidity and more volatile price movements. There is no guarantee that broker-dealers will continue to make a market in the securities, nor can the current share price level or trading volume be assured.